Lawrence P. Wennogle
Corporate Officer/Principal at ITI, Inc. (New York)
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sharon Mates | M | 71 |
Intra-Cellular Therapies, Inc. /Old/
 Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 22 years |
| Lawrence Hineline | M | 67 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 22 years |
| Michael Rawlins | M | 82 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 2 years |
| Chris D. Alafi | M | 60 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 11 years |
| Michael Halstead | M | 51 |
ITI, Inc. (New York)
| 10 years |
| Allen A. Fienberg | M | 64 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 12 years |
| Kimberly E. Vanover | M | 58 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 7 years |
| Rory Riggs | M | 71 |
ITI, Inc. (New York)
| 10 years |
| Joel Marcus | M | 76 |
ITI, Inc. (New York)
| 18 years |
| Robert van Nostrand | M | 67 |
ITI, Inc. (New York)
| 10 years |
| Juan F. Sanchez | M | - | 10 years | |
| Mark Neumann | M | 61 | 6 years | |
| Robert Davis | M | 73 | 9 years | |
| Suresh Durgam | M | 55 | 6 years | |
| Michael Olchaskey | M | - | 6 years | |
| John A. Bardi | M | - | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Samir Naji Masri | M | 79 | - | |
| Richard Alan Lerner | M | 85 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY. | 19 years |
| Virapan Pulges | M | 64 |
The University of Colorado
| 6 years |
| Chris K. Blackwood | M | - |
The University of Colorado
| 5 years |
| Douglas Pasquale | M | 69 |
The University of Colorado
| 4 years |
| David V. Hampton | M | - |
The University of Colorado
| 1 years |
| Dewey P. Bushaw | M | - |
The University of Colorado
| 4 years |
| Carl Demartini | M | - |
The University of Colorado
| 4 years |
| Suhail Qadi | M | - |
The University of Colorado
| 3 years |
| Scott C. Helbing | M | - |
The University of Colorado
| 2 years |
| Steven G. Judd | M | - |
The University of Colorado
| 4 years |
| Richard Marc Gordon | M | - |
The University of Colorado
| 2 years |
| Samuel D. Winegrad | M | - |
The University of Colorado
| 4 years |
| Michael S. Newman | M | - |
The University of Colorado
| 4 years |
| Khalifa Al-Mulhem | M | 72 |
The University of Colorado
| 4 years |
| Robert M. Bearman | M | - |
The University of Colorado
| 3 years |
| Paul Greengard | M | - | - | |
| Dana M. Latimer-Sittig | F | - |
The University of Colorado
| 4 years |
| Dennis J. LaPoint | M | - |
The University of Colorado
| 3 years |
| Douglas A. Miller | M | 73 |
The University of Colorado
| 4 years |
| Dean Stoecker | M | 67 |
The University of Colorado
| 4 years |
| Jo Anne Miller | F | - |
The University of Colorado
| 4 years |
| James M. Poage | M | 71 |
The University of Colorado
| 4 years |
| Tom Rutledge | M | - |
The University of Colorado
| 4 years |
| John Wojick | M | - |
The University of Colorado
| 4 years |
| Andrew Satlin | M | 69 | 3 years | |
| Mike McCrory | M | - |
The University of Colorado
| 4 years |
| James Hohenstein | M | - |
The University of Colorado
| 4 years |
| Kevin Kinzie | M | - |
The University of Colorado
| 4 years |
| Salim Abdulkarim Ali Al-Lawzi | M | 83 |
The University of Colorado
| 3 years |
| Thomas Kahl | M | - |
The University of Colorado
| 1 years |
| David Lacey | M | 71 |
The University of Colorado
| 4 years |
| Douglas G. Smith | M | - |
The University of Colorado
| 3 years |
| Jerry K. Sommer | M | - |
The University of Colorado
| 4 years |
| Susan Ormiston Christ | F | 65 |
The University of Colorado
| 4 years |
| Todd R. Kalstrom | M | 66 |
The University of Colorado
| 4 years |
| Ken Conyers | M | - |
The University of Colorado
| 4 years |
| Donald J. Martis | M | - |
The University of Colorado
| 4 years |
| John F. Reitnouer | M | - |
The University of Colorado
| 4 years |
| Richard Grigsby | M | - |
The University of Colorado
| 4 years |
| Mike B. van Sicklen | M | - |
The University of Colorado
| 4 years |
| William B. Mathews | M | 71 |
The University of Colorado
| 4 years |
| Michael O. Kokesh | M | - |
The University of Colorado
| 4 years |
| William Barker | M | 75 |
The University of Colorado
| 2 years |
| James J. Burke | M | 68 |
The University of Colorado
| 4 years |
| David W. Siple | M | 64 |
The University of Colorado
| 4 years |
| Catherine Rice | F | 64 |
The University of Colorado
| 4 years |
| Robert Hess | M | - |
The University of Colorado
| 3 years |
| Kathryn L. Hale | F | - |
The University of Colorado
| 4 years |
| John Joseph Girton | M | - |
The University of Colorado
| 2 years |
| J. Scott Konecny | M | - |
The University of Colorado
| 4 years |
| Ronald R. Snyder | M | 67 |
The University of Colorado
| 4 years |
| Dave Jordan | M | - |
The University of Colorado
| 4 years |
| Robert William Dunlap | M | - |
The University of Colorado
| 4 years |
| Michael J. Wozniak | M | 68 |
The University of Colorado
| 3 years |
| Philip N. Eggers | M | - |
The University of Colorado
| 4 years |
| Thomas A. Polich | M | 68 |
The University of Colorado
| 4 years |
| John Leone | M | 77 |
The University of Colorado
| 2 years |
| Christopher W. Roser | M | 66 |
The University of Colorado
| 4 years |
| Scott M. Freeman | M | 67 |
The University of Colorado
| 4 years |
| Terrance Shipp | M | - |
The University of Colorado
| 4 years |
| Pamela Saxton | F | 72 |
The University of Colorado
| 4 years |
| William J. Pincus | M | 70 |
The University of Colorado
| 4 years |
| Tom Forester | M | - |
The University of Colorado
| 4 years |
| Robert Bland | M | 71 |
The University of Colorado
| 4 years |
| Brad Colby | M | 67 |
The University of Colorado
| 4 years |
| H. Eric C. Peitz | M | - |
The University of Colorado
| 2 years |
| Stephen J. Gulotta | M | - |
The University of Colorado
| 4 years |
| Mark Nass | M | - |
The University of Colorado
| 4 years |
| Daniel A. Buttry | M | - |
The University of Colorado
| 4 years |
| Ethan Goller | M | - |
The University of Colorado
| 4 years |
| Isabella McCarthy | F | - |
The University of Colorado
| 4 years |
| Kevin O'Connor | M | - |
The University of Colorado
| 3 years |
| Alice Elliot | F | 66 |
The University of Colorado
| 4 years |
| Jeff V. Sutherland | M | - |
The University of Colorado
| 5 years |
| Dave Klenzendorf | M | - |
The University of Colorado
| 6 years |
| Karen Mathis | M | - |
The University of Colorado
| 3 years |
| Gretchen L. Jahn | F | - |
The University of Colorado
| 1 years |
| Theofanis G. Gavrilis | M | - |
The University of Colorado
| 4 years |
| James Gallogly | M | 71 |
The University of Colorado
| 4 years |
| Jeffrey Klenda | M | 67 |
The University of Colorado
| 4 years |
| Charles Sidney Cairns | M | - |
The University of Colorado
| 5 years |
| Doug L. Heller | M | - |
The University of Colorado
| 4 years |
| James Burke | M | 65 |
The University of Colorado
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lawrence P. Wennogle
- Personal Network
